- Home
- ADSK vs REGN Comparison
ADSK vs REGN Comparison
Compare ADSK & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADSK
- REGN
- Stock Information
- Founded
- ADSK 1982
- REGN 1988
- Country
- ADSK United States
- REGN United States
- Employees
- ADSK N/A
- REGN N/A
- Industry
- ADSK Computer Software: Prepackaged Software
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- ADSK Technology
- REGN Health Care
- Exchange
- ADSK Nasdaq
- REGN Nasdaq
- Market Cap
- ADSK 63.8B
- REGN 59.5B
- IPO Year
- ADSK N/A
- REGN 1991
- Fundamental
- Price
- ADSK $324.52
- REGN $568.20
- Analyst Decision
- ADSK Buy
- REGN Buy
- Analyst Count
- ADSK 25
- REGN 23
- Target Price
- ADSK $354.28
- REGN $794.83
- AVG Volume (30 Days)
- ADSK 1.7M
- REGN 991.3K
- Earning Date
- ADSK 08-28-2025
- REGN 10-30-2025
- Dividend Yield
- ADSK N/A
- REGN 0.62%
- EPS Growth
- ADSK N/A
- REGN 5.03
- EPS
- ADSK 4.81
- REGN 39.67
- Revenue
- ADSK $6,605,000,000.00
- REGN $14,214,200,000.00
- Revenue This Year
- ADSK $15.98
- REGN N/A
- Revenue Next Year
- ADSK $11.12
- REGN $4.97
- P/E Ratio
- ADSK $67.45
- REGN $14.32
- Revenue Growth
- ADSK 13.78
- REGN 5.38
- 52 Week Low
- ADSK $232.67
- REGN $476.49
- 52 Week High
- ADSK $329.09
- REGN $1,170.58
- Technical
- Relative Strength Index (RSI)
- ADSK 68.24
- REGN 50.07
- Support Level
- ADSK $321.97
- REGN $552.98
- Resistance Level
- ADSK $329.09
- REGN $588.70
- Average True Range (ATR)
- ADSK 6.64
- REGN 16.19
- MACD
- ADSK 3.20
- REGN -3.04
- Stochastic Oscillator
- ADSK 90.35
- REGN 26.70
About ADSK Autodesk Inc.
Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction; product design and manufacturing; and media and entertainment. Autodesk software enables design, modeling, and rendering needs of these industries. The company has over 4 million paid subscribers across 180 countries.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).